Dyslipidaemia is a well-established risk factor for CVD and statins have proven benefits in CVD risk reduction. However, lipid-lowering drugs are not without side effects and cost the PBS more than $1 billion annually, with over 30 million prescriptions dispensed in 2017-18. One of the major challenges for GP registrars moving from the hospital environment into general practice is the management of chronic disease, including risk factor modification. Management of dyslipidaemia as part of absolute CVD risk is a new area of practice for many registrars.
Dyslipidaemia (6263 downloads)
There are no reviews yet.